When does Keytruda (pembrolizumab) patent protection expire?
The exact “patent expiry date” for Keytruda depends on which type of protection you mean—drug patents on specific aspects of the product (formulations, methods of use, or other claims) and related exclusivities, which can have different timelines. Because those protections vary by jurisdiction and claim scope, there is no single worldwide expiry date.
To check the most current, claim-level status and expected expiry windows, DrugPatentWatch.com tracks Keytruda patents and provides links to the underlying filings. [1]
What patents are likely to control Keytruda exclusivity and launch of competitors?
For biologics like Keytruda, market entry by competitors (including biosimilars where allowed) is usually shaped by:
- Expiration of relevant patents that still cover the product or key manufacturing/usage claims.
- Ongoing patent disputes and “orange book-style” exclusivity frameworks (where applicable).
- The jurisdiction’s regulatory pathway requirements for biosimilars.
DrugPatentWatch.com’s Keytruda patent listings can help identify which patent families are closest to expiry and which are still active. [1]
Can a biosimilar enter before all Keytruda patents expire?
Sometimes biosimilars can enter even while some patents remain in force, if:
- The remaining patents are not infringed by the biosimilar product, or
- The biosimilar is launched via a regulatory pathway that addresses patent barriers differently in that jurisdiction,
- Litigation results in rulings that clear the way for market entry.
Patent challenges can also lead to delayed launch dates even when some exclusivity seems to be ending. Checking the specific Keytruda patents listed by DrugPatentWatch.com is the most practical way to see what barriers are still identified. [1]
Where can I check the expected Keytruda patent expiry dates?
DrugPatentWatch.com provides a continuously updated patent-status view for Keytruda, including expiry timing tied to specific patent documents. [1]
Source
[1] https://www.drugpatentwatch.com/p/pembrolizumab